Is Laurus Labs overvalued or undervalued?

As of 17 October 2025, the valuation grade for Laurus Labs has moved from expensive to very expensive. This indicates that the company is currently overvalued. Key ratios supporting this conclusion include a PE ratio of 95.61, an EV to EBITDA ratio of 40.49, and a Price to Book Value of 10.88. Compared to its peers, Laurus Labs significantly exceeds the PE ratio of Sun Pharma (35.16) and the EV to EBITDA ratio of Cipla (16.66), further highlighting its overvaluation. In the context of recent performance, Laurus Labs has outperformed the Sensex, with a year-to-date return of 49.62% compared to the Sensex's 7.44%. This strong performance may not be sustainable given its current valuation metrics, suggesting that investors should approach with caution.